You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 301 No. 14, April 8, 2009 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Bacterial Infections
 •Pulmonary Diseases
 •Chronic Obstructive Pulmonary Disease
 •Pneumonia
 •Statistics and Research Methods
 •Drug Therapy
 •Adverse Effects
 •Drug Therapy, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Drs Loke and Singh hypothesize that a substantial proportion of the serious adverse events reported in the study by Burge et al1 may have been COPD exacerbations rather than pneumonia. Lack of explicit definitions of pneumonia may alter the observed association of inhaled corticosteroids with increased pneumonia rates. However, because inhaled corticosteroids reduce COPD exacerbation rates, this form of misclassification would tend to bias estimates of pneumonia risk toward the null, underestimating the actual risk of pneumonia associated with inhaled corticosteroids.

Loke and Singh also suggest that the inclusion of unpublished clinical trial data (GlaxoSmithKline Clinical Trial Register for Burge et al1 and UK Medicines and Healthcare Regulatory Authority safety newsletter for Calverley et al, 20072) may refine the estimate of pneumonia risk we reported. Including unpublished data in meta-analyses remains controversial due to the lack of quality control and associated peer review of these data.3

While . . . [Full Text of this Article]

M. Bradley Drummond, MD, MHS
mdrummo3@jhmi.edu

Eddy Fan, MD
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University
Baltimore, Maryland



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease
Yoon K. Loke and Sonal Singh
JAMA. 2009;301(14):1432.
EXTRACT | FULL TEXT  

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease
James Wall and Imran Aziz
JAMA. 2009;301(14):1432-1433.
EXTRACT | FULL TEXT  

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease
Finn Radner and Ulf Nihlén
JAMA. 2009;301(14):1433.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.